CPTx Unveils DNA-Based CAR T Data, Challenging Cancer Therapy's Limits

MUNICH, Germany – May 04, 2026 – A German biotechnology firm is poised to present data on what it hopes will be the next evolution in cancer treatment: an "off-the-shelf" CAR T therapy created directly inside the patient's body. CPTx, a preclinical-stage company, announced today it will share preclinical proof-of-principle for its DNA-based in vivo CAR T platform at the upcoming American Society of Gene & Cell Therapy (ASGCT) Annual Meeting in Boston.

The announcement signals a significant step in the race to overcome the profound limitations of current CAR T therapies. The company's oral presentation will feature early results from mouse models, where its approach reportedly achieved more durable tumor control compared to mRNA-based alternatives, potentially heralding a more persistent and accessible form of the revolutionary cancer treatment.

The Promise of an 'In Vivo' Revolution

Chimeric antigen receptor (CAR) T-cell therapy has been a game-changer for certain blood cancers. By reprogramming a patient's own immune T cells to hunt and destroy cancer, treatments like Kymriah and Yescarta have offered hope where none existed. However, this power comes at a steep price.

The current ex vivo process is a logistical and medical marathon: a patient's T cells are extracted, frozen, shipped to a centralized lab, genetically engineered, multiplied over weeks, and then shipped back to be infused into the same patient. This bespoke manufacturing process is not only astronomically expensive—with treatments costing hundreds of thousands of dollars—but it also creates significant delays for critically ill patients and restricts access to highly specialized medical centers. The global CAR T market, valued in the billions and projected to grow exponentially, is grappling with these challenges of scalability and cost.

This is the problem in vivo therapies aim to solve. By engineering the CAR T cells directly within the body, the entire external manufacturing step could be eliminated. The therapy would transform from a complex, individualized procedure into a systemically administered drug, much like a standard infusion.

"By shifting CAR T therapy from an ex vivo product to an in vivo medicine using our unique DNA-based vectors, this platform has the potential to substantially expand patient access," said Hendrik Dietz, CEO of CPTx, in the company's press release.

Decoding CPTx's DNA-Based Approach

While several companies are pursuing the in vivo dream, CPTx is carving out a niche with its unique technological foundation. The core of its platform consists of two key components: "immune-quiet" single-stranded DNA (ssDNA) and targeted lipid nanoparticles (tLNPs).

The use of DNA is a critical differentiator. Much of the recent buzz in the in vivo space, fueled by the success of COVID-19 vaccines, has centered on messenger RNA (mRNA) delivered via LNPs. While effective, mRNA provides only transient gene expression; the instructions to build the cancer-fighting CAR proteins last for a limited time before degrading. This may be ideal for some applications, but for durable cancer control, a more persistent effect is often necessary.

CPTx's preclinical data, to be presented by Head of Strategy and R&D Matthias Bozza, directly addresses this point. The company states that its CAR-encoding DNA payloads achieved "more durable tumor control relative to mRNA-based particles." This suggests that using DNA could lead to a more sustained and controllable level of CAR expression, potentially preventing cancer relapse by keeping the engineered T cells active for longer.

The second innovation is the "immune-quiet" nature of its ssDNA vectors. A major historical hurdle for DNA-based therapies has been the tendency of the body's immune system to recognize foreign DNA and mount an inflammatory response. CPTx claims its proprietary vectors are designed to mitigate this DNA-induced inflammation, which could allow for safer administration and the possibility of repeat dosing if needed. These engineered DNA strands are packaged into tLNPs, which act as a sophisticated delivery vehicle, designed to home in on T cells after being administered systemically.

Navigating a Crowded and High-Stakes Field

CPTx is entering a fiercely competitive arena. The potential to create a scalable, off-the-shelf CAR T therapy has ignited a gold rush among biotech firms and attracted massive investments from big pharma. The in vivo CAR T market is forecast to surge from an estimated $650 million in 2025 to over $30 billion by 2033.

Several high-profile deals have underscored the industry's conviction. AbbVie's $2.1 billion acquisition of Capstan Therapeutics and Bristol Myers Squibb's $1.5 billion deal for Orbital Therapeutics, both focused on RNA-based in vivo platforms, highlight the immense value placed on this technology. Other players like Umoja and Interius BioTherapeutics are tackling the problem with viral vectors, while a host of companies including Moderna and CREATE Medicines are advancing their own non-viral mRNA-LNP approaches.

In this crowded landscape, CPTx's focus on DNA provides a distinct strategic angle. While mRNA's transient nature is being explored for autoimmune diseases where a temporary effect is desirable, CPTx's pursuit of durable expression positions it squarely in the oncology field, where long-term remission is the ultimate goal. If the company can successfully demonstrate that its DNA platform offers superior persistence and efficacy without compromising safety, it could carve out a significant competitive advantage.

From Preclinical Promise to Clinical Reality

The data CPTx plans to present at ASGCT represents a crucial, albeit early, milestone. Demonstrating durable tumor control in a mouse model is a vital proof-of-principle, suggesting the in vivo generated cells are functional and persistent. However, the path from preclinical success to a clinically approved therapy is long and fraught with challenges.

The history of drug development is littered with therapies that showed great promise in mice only to fail in human trials. The human immune system and tumor microenvironment are vastly more complex than any animal model can fully replicate.

Furthermore, novel gene therapies face a high regulatory bar. Agencies like the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) require extensive data on safety, biodistribution (where the drug goes in the body), and potential off-target effects. For a platform like CPTx's, regulators will scrutinize the "immune-quiet" claims, the efficiency and specificity of the LNP targeting, and the long-term fate of the administered DNA. Manufacturing consistency and quality control (CMC) is another major hurdle that has delayed or derailed many cell and gene therapy programs.

CPTx's stated goal is to establish a "translational path toward...first-in-human clinical evaluation." The upcoming presentation will offer the first public glimpse into the strength of its foundational data, providing a critical data point for investors, competitors, and patients eagerly awaiting the next leap forward in cancer therapy. The company's journey will be a key indicator of whether DNA-based vectors can truly unlock the full potential of making CAR T therapy a universally accessible medicine.